What is CUSIP 60770K107?

CUSIP 60770K107 is the security identifier used in SEC filing datasets for MRNA - Moderna, Inc. - Common Stock.

Who owns MRNA - Moderna, Inc. - Common Stock based on 13F filings?

775 institutions reported positions in MRNA - Moderna, Inc. - Common Stock as of Q2 2026. Open the latest holders period and ownership history tables on this page for position-level details.

Security Snapshot

Moderna, Inc. - Common Stock (MRNA) Institutional Ownership

CUSIP: 60770K107

13F Institutional Holders and Ownership History from Q4 2018 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

775

Shares (Excl. Options)

318,656,671

Price

$70.03

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock
Symbol: MRNA on Nasdaq
All holders as of 30 Jun 2026: Q2 2026
Total 13F shares: 318,656,671
Total 13F value: $22,295,451,794
Portfolio coverage rank: 0.01%
Share change: +10,872,923
Value change: +$822,521,305
Number of holders: 775
Shares outstanding: 397,803,500
SEC-reported price per share: $57.92
Insider filing price: $57.92

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

MRNA - Moderna, Inc. - Common Stock is tracked under CUSIP 60770K107.
775 institutions reported positions in Q2 2026.
4 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 722 to 775 between Q1 2026 and Q2 2026.
SEC-reported value moved from $15,630,951,628 to $22,295,451,794.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 775 institutions filings for Q2 2026.

Open SEC evidence

Security key

60770K107

Latest holder period

Q2 2026

13F holders

775

13D/G owners

CIK / CUSIP context first

Open Q2 2026 holders MRNA full holder history Moderna, Inc. SEC filings Moderna, Inc. company facts Moderna, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 60770K107:

Q2 2026 (775 holders) Q1 2026 (722 holders) Q4 2025 (665 holders) Q3 2025 (634 holders) Q2 2025 (663 holders) Q1 2025 (678 holders) Q4 2024 (729 holders) Q3 2024 (765 holders) Q2 2024 (939 holders) Q1 2024 (887 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

MRNA

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	13%	+23%	$3,471,378,759	+$703,767,298	51,803,891	+25%	FMR LLC	30 Jun 2026
VANGUARD CAPITAL MANAGEMENT LLC	6.5%		$1,317,438,259		25,933,824		Vanguard Capital Management	31 Mar 2026
Capital World Investors	5.6%		$1,492,781,502		22,276,996		Capital World Investors	30 Jun 2026
BAILLIE GIFFORD & CO	4.6%	-14%	$1,275,020,663	-$166,232,732	18,206,778	-12%	BAILLIE GIFFORD & CO	30 Jun 2026

As of 30 Jun 2026, 775 institutional investors reported holding 318,656,671 shares of Moderna, Inc. - Common Stock (MRNA). This represents 80% of the company’s total 397,803,500 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share

66%

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
FMR LLC	13%	51,859,891	+14%	0.16%	$3,631,748,191
BlackRock, Inc.	7.7%	30,599,409	+3.3%	0.03%	$2,142,876,625
VANGUARD CAPITAL MANAGEMENT LLC	5.8%	23,208,792	+1.5%	0.03%	$1,625,311,704
Capital World Investors	5.6%	22,276,996	+19%	0.18%	$1,560,053,964
BAILLIE GIFFORD & CO	4.6%	18,206,778	-8.9%	1.2%	$1,275,020,663
STATE STREET CORP	4%	15,726,193	+5.8%	0.03%	$1,101,305,296
VANGUARD PORTFOLIO MANAGEMENT LLC	3.9%	15,581,313	-0.22%	0.05%	$1,091,159,349
GEODE CAPITAL MANAGEMENT, LLC	2.4%	9,710,335	+2.9%	0.04%	$678,818,969
MORGAN STANLEY	2.4%	9,538,093	+13%	0.04%	$667,952,773
Theleme Partners LLP	2%	8,057,571	+0.12%	34%	$564,271,697
TWO SIGMA INVESTMENTS, LP	1.8%	7,193,530	-21%	0.38%	$503,762,906
Invesco Ltd.	1.5%	5,780,299	+21%	0.03%	$404,794,349
PRICE T ROWE ASSOCIATES INC /MD/	1.4%	5,589,560	+657%	0.04%	$391,438,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	1.2%	4,838,884	+2.2%	0.05%	$338,867,047
GOLDMAN SACHS GROUP INC	1.2%	4,671,950	-29%	0.03%	$327,176,636
Flagship Pioneering, LLC	1.2%	4,632,149	0%	21%	$324,389,395
UBS Group AG	1.1%	4,463,211	+1.3%	0.05%	$312,558,666
BNP PARIBAS FINANCIAL MARKETS	1.1%	4,377,120	0%	0.16%	$306,529,714
NORGES BANK	0.76%	3,026,074		0.02%	$211,915,962
NORTHERN TRUST CORP	0.75%	2,985,329	+1.1%	0.02%	$209,062,589
BANQUE PICTET & CIE SA	0.68%	2,699,402	-1.8%	1.9%	$189,039,122
DIMENSIONAL FUND ADVISORS LP	0.62%	2,468,775	+16%	0.03%	$172,876,329
WELLINGTON MANAGEMENT GROUP LLP	0.62%	2,461,574	+4.4%	0.03%	$172,384,027
Merck & Co., Inc.	0.58%	2,308,190	0%	31%	$161,642,545
CITIGROUP INC	0.54%	2,165,414	+46%	0.07%	$151,643,942

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

Q2 2026

Rows shown

1-25 of 31

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q2	318,656,671	$22,295,451,794	+$822,521,305	$1,484,396,034	$1,468,912,457	$70.03	775
2026 Q1	308,074,337	$15,630,951,628	+$503,917,221	$1,552,767,231	$1,529,510,069	$50.80	722
2025 Q4	304,074,444	$8,970,220,798	+$762,808,902	$1,286,279,687	$1,214,563,127	$29.49	665
2025 Q3	275,125,683	$7,105,644,631	-$450,789,607	$1,128,519,908	$1,035,847,251	$25.83	634
2025 Q2	291,423,621	$8,041,462,409	+$359,301,164	$953,917,304	$778,127,109	$27.59	663
2025 Q1	278,813,548	$7,903,142,271	-$59,165,632	$879,746,945	$673,661,963	$28.35	678
2024 Q4	276,578,373	$11,499,056,660	+$341,051,932	$1,001,589,736	$786,508,119	$41.58	729
2024 Q3	260,519,054	$17,396,828,362	-$359,670,897	$1,243,213,357	$701,421,710	$66.83	765
2024 Q2	261,395,055	$31,036,767,708	-$43,788,037	$1,431,835,450	$1,094,475,375	$118.75	939
2024 Q1	262,225,074	$27,942,962,472	+$671,576,108	$993,221,671	$1,286,942,056	$106.56	887
2023 Q4	256,350,763	$25,504,353,761	+$907,888,206	$1,079,174,407	$1,499,592,291	$99.45	869
2023 Q3	246,373,071	$25,443,040,671	-$303,969,124	$1,068,658,896	$1,316,134,609	$103.29	872
2023 Q2	246,506,415	$29,955,571,272	-$272,422,709	$1,008,405,288	$874,358,642	$121.50	942
2023 Q1	249,344,037	$38,273,515,844	+$239,644,701	$1,358,217,438	$1,574,550,446	$153.58	996
2022 Q4	248,479,248	$44,642,318,628	+$419,105,140	$2,336,618,593	$2,478,808,951	$179.62	1,049
2022 Q3	246,689,392	$29,178,218,716	+$223,399,465	$1,254,027,475	$1,052,298,869	$118.25	882
2022 Q2	244,256,119	$34,891,994,437	-$466,757,538	$1,485,721,310	$1,271,813,410	$142.85	957
2022 Q1	248,043,088	$42,733,575,812	+$209,409,354	$2,950,839,880	$2,493,864,042	$172.26	983
2021 Q4	246,080,857	$62,455,582,704	-$6,658,229	$6,423,558,004	$4,434,992,654	$253.98	1,078
2021 Q3	225,302,088	$86,681,348,769	+$6,751,024,992	$8,721,579,062	$7,515,706,532	$384.86	1,120
2021 Q2	207,880,167	$48,837,794,090	+$5,169,371,723	$4,129,479,856	$3,516,026,784	$234.98	873
2021 Q1	188,072,205	$24,617,994,062	+$2,907,518,589	$2,100,566,245	$1,820,607,735	$130.95	752
2020 Q4	168,732,531	$17,626,423,609	-$527,763,419	$1,688,796,948	$1,263,437,595	$104.47	688
2020 Q3	204,933,447	$14,493,668,331	-$999,957,835	$707,320,000	$543,636,000	$70.75	535
2020 Q2	219,125,612	$14,064,229,526	+$1,607,162,122	$355,581,000	$412,038,000	$64.21	477